Since the first therapeutic antibody Muromonab-CD3 was approved in 1986, more than 100 antibodies have been approved for marketing. Based on their properties, antibodies can be divided into four categories: mouse antibodies,Read More…
The path to finding a therapeutic antibody that leads to significant medical improvements is often complicated, long, and costly. Many criteria have to be taken into account in order to begin theRead More…
Following the 2018 Nobel Prize for Medicine, global attention is now more than ever turned toward the promise of immunotherapy in oncology. According to a recent study published in the international journalRead More…
Checkpoint inhibitor drugs, those that pull the brakes off the immune system, can cause dramatic improvements in cancer patients, but the benefits are far from universal. In the case of atezolizumab (Tecentriq),Read More…
“A new article outlines a pioneering method of screening a person’s diverse set of antibodies for rapid therapeutic discovery. Antibody proteins are an important part of the human immune system that specificallyRead More…
Keytruda (pembrolizumab) is a drug developed by Merck (or MSD outside of the U.S. and Canada). It has been approved by the U.S. Food and Drug Administration (FDA) and the European Commission for the treatment of aRead More…
At the beginning of this month, European Commission (EC) has approved an expanded indication for XGEVA® (denosumab) for the prevention of skeletal-related events (SRE) in adults with advanced malignancies involving bone, basedRead More…
“A team of investigators has found a way to engineer antibodies within an organism, converting autoantibodies that attack ‘self’ tissues into anti-inflammatory antibodies in animal models of two autoimmune diseases.” A teamRead More…